Uttroside-B

About Q BioMed

Q BioMed operates as a development-stage biopharmaceutical company with a portfolio strategy aimed at de-risking the traditional drug development pathway. The company seeks to in-license or acquire promising biomedical assets, particularly small molecules, and advance them through clinical development and commercialization. Its approach is to create a pipeline spanning various therapeutic areas to share infrastructure costs and balance potential successes against failures. As a publicly traded entity, it aims to provide shareholder value by efficiently moving technologies toward monetization events.

Therapeutic Areas